Thus, the application of IL-33 inhibitors or enhancement of mast cells and fibroblasts to produce the decoy receptor sST2 might significantly slow the progression of pulmonary fibrosis development, and inhibiting this process can help to reduce the possibility of pulmonary fibrosis patients developing lung cancer. Here, IL33 is linked to lung carcinoma.